From the publishers of JADPRO

Multiple Myeloma Resource Center


Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study

Last Updated: Tuesday, August 22, 2023

Data from the SEER-Medicare (1999-2017) database was assessed, looking at the differences in survival between non-Hispanic Black (NHB) and non-Hispanic white (NHW) patients with multiple myeloma. NHB patients with MM were less likely to receive novel antimyeloma treatment and ASCT compared with NHWs, and these disparities in treatment could not be explained by sociodemographic factors. Overall survival was comparable between across the entire population, but NHB patients had a superior survival when they were treated similar as NHW patients.  

Blood Cancer Journal
News & Literature Highlights

Transplantation and Cellular Therapy

Patient-reported outcomes in long-term survivors of autologous hematopoietic cell transplantation in multiple myeloma

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations


Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Clinical Journal of Oncology Nursing

Steroid-associated side effects: A symptom management update on multiple myeloma treatment

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis


Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)


Increased COVID-19 breakthrough infection risk after SARS-CoV-2 vaccine boosting in patients with plasma cell disorders: A large nationwide Veterans Affairs study

ASCO 2023

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

U.S. Food & Drug Administration

FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma

Leukemia and Lymphoma

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: A population-based study